Literature DB >> 10908655

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

S Cariou1, J C Donovan, W M Flanagan, A Milic, N Bhattacharya, J M Slingerland.   

Abstract

Estrogens and antiestrogens influence the G(1) phase of the cell cycle. In MCF-7 breast cancer cells, estrogen stimulated cell cycle progression through loss of the kinase inhibitor proteins (KIPs) p27 and p21 and through G(1) cyclin-dependent kinase (cdk) activation. Treatment with antiestrogen drugs, Tamoxifen or ICI 182780, caused cell cycle arrest, with up-regulation of both p21 and p27 levels, an increase in their binding to cyclin E-cdk2, and kinase inhibition. The requirement for these KIPs in the arrests induced by estradiol depletion or by antiestrogens was investigated with antisense. Antisense inhibition of p21 or p27 expression in estradiol-depleted or antiestrogenarrested MCF-7 led to abrogation of cell cycle arrest, with loss of cyclin E-associated KIPs, activation of cyclin E-cdk2, and S phase entrance. These data demonstrate that depletion of either p21 or p27 can mimic estrogen-stimulated cell cycle activation and indicate that both of these KIPs are critical mediators of the therapeutic effects of antiestrogens in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908655      PMCID: PMC16818          DOI: 10.1073/pnas.160016897

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

Authors:  A Howell; D DeFriend; J Robertson; R Blamey; P Walton
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

Review 2.  G1 phase progression: cycling on cue.

Authors:  C J Sherr
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

3.  Androgen receptors in endocrine-therapy-resistant human prostate cancer.

Authors:  T H van der Kwast; J Schalken; J A Ruizeveld de Winter; C C van Vroonhoven; E Mulder; W Boersma; J Trapman
Journal:  Int J Cancer       Date:  1991-05-10       Impact factor: 7.396

4.  Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein.

Authors:  S Bates; D Parry; L Bonetta; K Vousden; C Dickson; G Peters
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

5.  Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.

Authors:  C A Encarnación; D R Ciocca; W L McGuire; G M Clark; S A Fuqua; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 6.  Cell cycle control by steroid hormones.

Authors:  E A Musgrove; R L Sutherland
Journal:  Semin Cancer Biol       Date:  1994-10       Impact factor: 15.707

7.  Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.

Authors:  C K Watts; K J Sweeney; A Warlters; E A Musgrove; R L Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

Authors:  J A Ruizeveld de Winter; P J Janssen; H M Sleddens; M C Verleun-Mooijman; J Trapman; A O Brinkmann; A B Santerse; F H Schröder; T H van der Kwast
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

9.  Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition.

Authors:  I Hoffmann; G Draetta; E Karsenti
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

10.  Cdc25A is a novel phosphatase functioning early in the cell cycle.

Authors:  S Jinno; K Suto; A Nagata; M Igarashi; Y Kanaoka; H Nojima; H Okayama
Journal:  EMBO J       Date:  1994-04-01       Impact factor: 11.598

View more
  80 in total

1.  ER beta inhibits proliferation and invasion of breast cancer cells.

Authors:  G Lazennec; D Bresson; A Lucas; C Chauveau; F Vignon
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

2.  p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.

Authors:  Isabel Chu; Jun Sun; Angel Arnaout; Harriette Kahn; Wedad Hanna; Steven Narod; Ping Sun; Cheng-Keat Tan; Ludger Hengst; Joyce Slingerland
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

3.  Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.

Authors:  Lara H El Touny; Anthony Vieira; Arnulfo Mendoza; Chand Khanna; Mark J Hoenerhoff; Jeffrey E Green
Journal:  J Clin Invest       Date:  2013-12-09       Impact factor: 14.808

4.  MicroRNA and transcription factor mediated regulatory network for ovarian cancer: regulatory network of ovarian cancer.

Authors:  Huanchun Ying; Jing Lv; Tianshu Ying; Jun Li; Qing Yang; Yuan Ma
Journal:  Tumour Biol       Date:  2013-08-29

5.  Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.

Authors:  Kibeom Jang; Hyunho Yoon; Karina E Hew; Fiona Simpkins; Minsoon Kim; Diana J Azzam; Jun Sun; Dekuang Zhao; Tan A Ince; Wenbin Liu; Wei Guo; Zhi Wei; Gao Zhang; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2018-06-29       Impact factor: 12.531

Review 6.  Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.

Authors:  Elizabeth A Musgrove; Elizabeth A Davison; Christopher J Ormandy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 7.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 8.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 9.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

10.  14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer.

Authors:  Bing Wang; Kang Liu; Hui-Yi Lin; Naresh Bellam; Shiyun Ling; Weei-Chin Lin
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.